User:Mr. Ibrahem/Tucatinib

Tucatinib, sold under the brand name Tukysa, a medication used to treat HER2-positive breast cancer. Specifically it is used in cases which are localized but advanced or which have spread to other parts of the body. It is used together with capecitabine and trastuzumab when other treatments have not worked. It is taken by mouth.

Common side effects include diarrhea, nausea, tiredness, inflammation of the mouth, liver problems, and rash. A rash that may occur is known as palmar-plantar erythrodysesthesia. Use during pregnancy may harm the baby. It is a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2).

Tucatinib was approved for medical use in the United States and Australia in 2020, and in Europe in 2021. In the United States it costs about 21,000 USD per month as of 2021.